The updated strategic direction consists of a plan to approach clinical activities and includes several strategic initiatives, among these are:

• Continued investments into R&D to develop the next-generation technology
• Standardization of the product portfolio
• Further development of OEM (original equipment manufacturer) channels
• Strategic collaboration with Mentice's largest industry clients.

To support the strategic direction, Mentice has updated its financial targets while clarifying that the company’s main ambition is continued growth while gradually improving profitability:

• 20-30 per cent annual growth in Net sales.
• EBITDA margin in the mid-term (three years) of 20 per cent with a longer-term target of 30 per cent EBITDA margin.
  

“This is formally our first capital market day since our IPO and we are looking forward to present strategi, product as well as two customer examples”, says Göran Malmberg, Mentice CEO, “we believe this is great opportunity to better explain what Mentice stand for.”

 In addition to the management team, Dr Demetrius Lopes, Director of Cerebrovascular and Comprehensive Stroke Center at Advocate Health Care, Chicago, USA, and Michael Lee, Director of EBR Systems, Ireland, will participate in the Capital Markets Day and discuss trends within IGIT and Mentice’s solutions.

The event will take place from 13:00 to 16:00 CET and will be held in person at Sergelkonferensen, Mäster Samuelsgatan 42, Stockholm. The Capital Markets Day will also be webcast live for those unable to attend in person.

During the event, there will be a demonstration of Mentices products and solutions and an opportunity to ask questions directly to any of the presenters. For a complete agenda and more information about the event and to register, please visit: https://www.mentice.com/event/cmd-2024